X
X
Total 393357 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Angular gyrus | Part of inferior parietal lobule formed by the cortex surrounding the upturned end of the superior temporal sulcus (Nolte, The Human Brain, 6th ed, 2009, pg 659) | ILX:0100627 | 13 | scicrunch | 06/23/2020 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Angular Step | The angular scan arc step between views of the TOMO acquisition, in degrees. | ILX:0100628 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Angular sulcus | The term angular sulcus (H) refers to a superficial feature of the parietal lobe. It is the portion of the superior temporal sulcus that extends into the angular gyrus (Ono-90). (NN) | ILX:0100629 | 8 | scicrunch | 06/23/2020 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Angular velocity | A physical quality inhering in a bearer by virtue of the rate of its angular movement about an axis; the angle rotated in a given time. | ILX:0100630 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Angular View Vector | An array that contains the angular view number for each frame. | ILX:0100631 | 6 | scicrunch | 08/28/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Anidulafungin | Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin. (Wikipedia) Pharmacology: Anidulafungin is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans. Anidulafungin is an echinocandin, a class of antifungal drugs that inhibits the synthesis of 1,3--D-glucan, an essential component of fungal cell walls. Anidulafungin is active in vitro against Candida albicans, C. glabrata, C. parapsilosis, and C. tropicalis. Mechanism of action: Anidulafungin is a semi-synthetic echinocandin with antifungal activity. Anidulafungin inhibits glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3--D-glucan, an essential component of the fungal cell wall. Drug type: Approved. Investigational. Small Molecule. Drug category: Antibiotics, Antifungal | ILX:0100632 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Anileridine | Anileridine is a synthetic opioid and strong analgesic medication. It is a narcotic pain reliever used to treat moderate to severe pain. Narcotic analgesics act in the central nervous system (CNS) to relieve pain. Some of their side effects are also caused by actions in the CNS. Pharmacology: Anileridine, a potent analgesic, is an analog of pethidine. Anileridine is useful for the relief of moderate to severe pain. It may also be used as an analgesic adjunct in general anesthesia in the same manner as meperidine to reduce the amount of anesthetic needed, to facilitate relaxation, and to reduce laryngospasm. In addition, anileridine exerts mild antihistaminic, spasmolytic and antitussive effects. Anileridine's main pharmacologic action is exerted on the CNS. Respiratory depression, when it occurs, is of shorter duration than that seen with morphine or meperidine when equipotent analgesic doses are used. Mechanism of action: Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Opioids such as anileridine close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability. Drug type: Approved. Illicit. Small Molecule. Drug category: Analgesics. Narcotics. Opiate Agonists | ILX:0100633 | 5 | scicrunch | 08/24/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Animal Biobank | A cryogenic storage facility used to archive biological samples from non-human animals for use in research and experiments. Ranging in size from individual refrigerators to warehouses, animal biobanks are maintained by institutions such as universities and nonprofit organizations. (Adapted from Wikipedia) | ILX:0100634 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Animal model | Non-human animals, selected because of specific characteristics, for use in experimental research, teaching, or testing (adapted from MeSH via BioPortal: http://purl.bioontology.org/ontology/MESH/D023421) | ILX:0100635 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Animal naming task | animals are presented, usually pictorially, and participants are asked to name them aloud | ILX:0100636 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Animal physiology | Branch of physiology concerned with animals. | ILX:0100637 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Animal strain | Animals produced by the mating of littermates or siblings over multiple generations. The resultant strain of animals is virtually identical genotypically. Highly inbred animal lines allow the study of certain traits in a relatively pure form. (Segen, Dictionary of Modern Medicine, 1992) (MSH) | ILX:0100638 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Animal Temp Control | low noise heating system maintains animal body temperature during experimental procedures such as electrophysiological recordings where minimal electromagnetic interference is required. | ILX:0100639 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Animation software | A resource that provides an application or program that is used to rapidly display a sequence of images of 2-D or 3-D artwork or model positions in order to create an illusion of movement.NIRTC definition: Software application visualization using 'Animation'. | ILX:0100640 | 5 | scicrunch | 08/24/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Anion | A monoatomic or polyatomic species having one or more elementary charges of the electron. | ILX:0100641 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Anionic cys-loop ligand-gated ion channel | ILX:0100642 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Anisindione | Anisindione is a synthetic anticoagulant and an indanedione derivative. It prevents the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver by inhibiting the vitamin K mediated gamma-carboxylation of precursor proteins. Pharmacology: Anisindione is a synthetic anticoagulant and an indanedione derivative. It is prescribed only if you cannot take coumarin-type anticoagulants such as coumadin as anisindione is a powerful drug with serious potential side effects. Anticoagulants decrease the clotting ability of the blood and therefore help to prevent harmful clots from forming in the blood vessels. These medicines are sometimes called blood thinners, although they do not actually thin the blood. They also will not dissolve clots that already have formed, but they may prevent the clots from becoming larger and causing more serious problems. Mechanism of action: Like phenindione, to which it is related chemically, anisindione exercises its therapeutic action by reducing the prothrombin activity of the blood. Anisindione prevents the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver by inhibiting the vitamin Kmediated gamma-carboxylation of precursor proteins. Anisindione has no direct thrombolytic effect and does not reverse ischemic tissue damage, although it may limit extension of existing thrombi and prevent secondary thromboembolic complications. Drug type: Approved. Small Molecule. Drug category: Anticoagulants | ILX:0100643 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Anisotropine Methylbromide | Anisotropine methylbromide is a quaternary ammonium compound. Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents. Depending on the dose, anisotropine methylbromide may reduce the motility and secretory activity of the gastrointestinal system, and the tone of the ureter and urinary bladder and may have a slight relaxant action on the bile ducts and gallbladder. In general, smaller doses of anisotropine methylbromide inhibit salivary and bronchial secretions, sweating, and accommodation; cause dilatation of the pupil; and increase the heart rate. Larger doses are required to decrease motility of the gastrointestinal and urinary tracts and to inhibit gastric acid secretion. Pharmacology: Anisotropine methylbromide is a quaternary ammonium compound. Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents. Depending on the dose, anisotropine methylbromide may reduce the motility and secretory activity of the gastrointestinal system, and the tone of the ureter and urinary bladder and may have a slight relaxant action on the bile ducts and gallbladder. In general, smaller doses of anisotropine methylbromide inhibit salivary and bronchial secretions, sweating, and accommodation; cause dilatation of the pupil; and increase the heart rate. Larger doses are required to decrease motility of the gastrointestinal and urinary tracts and to inhibit gastric acid secretion. Mechanism of action: Quaternary ammonium compounds such as anisotropine methylbromide inhibit the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves as well as on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These postganglionic receptor sites are present in the autonomic effector cells of the smooth muscle, cardiac muscle, sinoatrial and atrioventricular nodes, and exocrine glands. Drug type: Approved. Small Molecule. Drug category: Anticholinergics. Parasympatholytics | ILX:0100644 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Anistreplase | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl group is chemically conjugated to a complex of bacterial-derived streptokinase and human Plasma-derived Lys-plasminogen proteins. Pharmacology: Anistreplase cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction. Mechanism of action: Anistreplase cleaves the Arg/Val bond in plasminogen to form plasmin. This in turn leads to the degradation of blood clots. Drug type: Approved. Biotech. Drug category: Thrombolytic Agents | ILX:0100645 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| ANKTM1 | ILX:0100646 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
About
Base community for the SciCrunch.org infrastructure
Contact Us
X